Certificazione DIN EN ISO 17100:2015-05 · TÜV DIN CERTCO Reg. 7U385
Membro Certificato ProZ.com Translation Network
Home › Blog e Analisi › EU Medical Device Regulation (MDR) Extension (Regulation 2023/607): Impact on Multilingual IFU Timelines

EU Medical Device Regulation (MDR) Extension (Regulation 2023/607): Impact on Multilingual IFU Timelines

Following the adoption of Regulation (EU) 2023/607 in March 2023 extending MDR transitional periods until 2027/2028, medical device manufacturers must meet strict May 2024 quality management milestones while maintaining multilingual Instructions for Use (IFUs).

Understanding Regulation (EU) 2023/607 Transitional Deadlines

To prevent acute shortages of life-saving medical devices across European hospitals caused by Notified Body capacity bottlenecks, the European Parliament and Council enacted Regulation (EU) 2023/607 on March 20, 2023. The amendment extends the validity of legacy directive certificates (MDD/AIMDD) until December 31, 2027 for higher-risk Class III and Class IIb implantable devices, and until December 31, 2028 for medium- and lower-risk Class IIb, Class IIa, and Class I sterile/measuring devices—subject to strict qualifying conditions.

EU MDR Regulation 2023/607 Translation – LIFE SCIENCES & MEDTECH
LIFE SCIENCES & MEDTECH — Professional Localization & Regulatory Quality Assurance (April 11, 2023)

Why Multilingual Technical Documentation Cannot Wait

Crucially, the extension is not an unconditional pause: manufacturers must implement an MDR-compliant Quality Management System (QMS) and lodge a formal Notified Body application no later than May 26, 2024. Furthermore, Article 10(11) language requirements remain fully enforceable upon MDR certification, requiring Instructions for Use (IFUs), labels, Implant Cards, and Summaries of Safety and Clinical Performance (SSCP) to be translated into up to 24 official EU languages in compliance with ISO 13485 quality workflows.

Executive Takeaways for Global Enterprises

  • Key Insight: Regulation (EU) 2023/607 extends MDR transition dates to 2027/2028 only for manufacturers who lodge formal applications by May 2024.
  • Key Insight: Post-Market Surveillance (PMS) and vigilance reporting must already comply with MDR standards across all EU markets.
  • Key Insight: Early localization of IFUs and SSCPs prevents last-minute commercialization bottlenecks once Notified Body certificates are issued.

Nota Editoriale e di Riferimento: Questa analisi tecnica è stata elaborata in modo indipendente dal dipartimento di ricerca di Alphatrad Worldwide per fini di approfondimento professionale e conformità settoriale. Per la documentazione ufficiale e gli atti di riferimento, consultare:

Fonte e Documentazione Ufficiale: EUR-Lex - Official Journal of the European Union (Regulation EU 2017/745) (https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0745)

Avete bisogno di traduzioni multilingue certificate, asseverazioni legali o localizzazione conforme agli standard ISO per i vostri progetti internazionali? Richiedete un preventivo gratuito personalizzato ad Alphatrad e riceverete un piano operativo dettagliato entro 24 ore.

← Ritorna alla lettura di tutti gli articoli Richiedi un Preventivo Gratuito →